Sign in

TAOX on Nasdaq

TAO Synergies Inc.

TAO Synergies Inc. is an American finance services company based in New York, incorporated in Delaware.1 Its shares trade on Nasdaq under the symbol TAOX.1

$3.60 up 0.10 (2.86%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

Compare with I-ON Digital Corp., SkyAI, Inc. or MedWellAI, Inc., or pick any stock.

  • TickerTAOX on Nasdaq1
  • IndustryFinance Services1
  • HeadquartersNew York, New York1
  • Incorporated inDE3
  • Business address1185 Avenue Of The Americas, 3Rd Floor, New York, Ny 100363
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

From August 23, 2013 to December 6, 2020, Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.) (the “Company” or “Synaptogenix”) was a wholly owned subsidiary of Neurotrope, Inc. (“Neurotrope”). Neurotrope’s operations were solely those of Synaptogenix. On May 17, 2020, Neurotrope announced plans for the complete legal and structural separation of Synaptogenix from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement between Neurotrope and Synaptogenix (the “Separation and Distribution Agreement”), Neurotrope distributed all of its equity interest in Synaptogenix to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in Synaptogenix, and Synaptogenix operates independently from Neurotrope. On December 6, 2020, Neurotrope approved the final distribution ratio and holders of record of Neurotrope common stock, …5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-3025.2%Operating margin6
-9609.2%Net margin6
-136.5%Return on equity6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue11¢$38.3K
  • Research and development89¢$322.2K

Out of $299.1K in revenue.6 The company lost money this year.

Financial statements

Revenue6$299.1K in 2025
0$100.0K$200.0K$300.0K2024: $0$020242025: $299.1K$299.1K2025
Operating income6-$9.0M in 2025+33% since 2024
-$10.0M-$7.5M-$5.0M-$2.5M02024: -$6.8M-$6.8M20242025: -$9.0M-$9.0M2025+33%
Net income78910116-$28.7M in 2025+90% since 2019
-$30.0M-$20.0M-$10.0M02019: -$15.1M-$15.1M20192020: -$12.7M-$12.7M2020−16%2021: -$12.6M-$12.6M2021−1%2022: -$5.6M-$5.6M2022−56%2023: -$6.0M-$6.0M2023+8%2024: -$12.8M-$12.8M2024+111%2025: -$28.7M-$28.7M2025+125%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Revenues from TAO staking$299.1K$0
Research and development$322.2K$1.6M
General and administrative$9.0M$5.2M
TOTAL OPERATING EXPENSES$9.3M$6.8M
OPERATING LOSS-$9.0M-$6.8M
Interest income$442.9K$1.3M
Share of net loss in equity investment-$44.5K
Loss on write-off of available for debt security-$2.4M
Loss on write-off of equity investment-$517.9K
Warrant issuance costs-$1.7M-$618.4K
Unrealized loss on digital assets-$10.5M
Change in fair value of Yuma partnership investments-$303.0K
Loss on issuance of Preferred Stock-$758.7K-$3.8M
Change in fair value of warrant liability-$12.4M-$829.0K
Change in fair value of derivative liability$5.6M$1.0M
TOTAL OTHER INCOME-$19.7M-$6.0M
Net income before income taxes-$28.7M-$12.8M
Provision for income taxes$0$0
Net income-$28.7M-$12.8M
Preferred Stock dividends$338.4K$789.9K
Net income attributable to common stockholders-$29.1M-$13.6M
Change in fair value of available for sale debt security$4.8K
Comprehensive loss-$29.1M-$13.6M
Basic income per common share (in dollars per share)-$8.81-$10.99
Fully diluted income per common share (in dollars per share)-$8.81-$10.99
Basic weighted average common shares outstanding (in shares)3.3M shares1.2M shares
Fully diluted weighted average common shares outstanding (in shares)3.3M shares1.2M shares

Compare TAO Synergies Inc. with another company

Corporate structure

TAO Synergies Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of TAO Synergies Inc.

  • TAO Synergies Inc. New York, New York
    • TAOX Florida Inc. Subsidiary · Florida, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What TAO Synergies Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$9.3K6 Dec 31, 2025$12.9K6 Dec 31, 2024−28.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.5M6 Dec 31, 2025$17.7M6 Dec 31, 2024−68.9%

Properties, in its own words

Our principal executive offices are currently located at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036, where we lease approximately 300 square feet of general office space for a total cost of approximately $6,300 per month. The lease for this office space expires on June 30, 2026 and is renewable for successive one year terms. We believe that our facilities are suitable and adequate for our needs for the foreseeable future.

Item 2 of the 10-K filed Mar 31, 2026.5

Leadership

Who has led TAO Synergies Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Alan J. Tuchman2021–2022

President

  1. Daniel L. Alkon2022
2025
Board members and other officers (7)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • EXECUTIVE CHAIRMANJOSHUA SILVERMAN named Sep 23, 2024 to Oct 24, 202521
  • CHIEF FINANCIAL OFFICERROBERT WEINSTEIN named Sep 23, 2024 to Oct 24, 202521
  • DirectorBRUCE BERNSTEIN named Sep 23, 2024 to Oct 24, 202521

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • TAOX Florida Inc. Florida4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Synaptogenix, Inc.Dec 10, 2020 to Jun 24, 20253
  • NEUROTROPE BIOSCIENCE, INC.Mar 13, 2013 to Nov 20, 20203

Timeline

  1. Dec 19, 20258-K Executive or director change; Shareholder vote22
  2. Oct 14, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure23
  3. Aug 29, 20258-K Executive or director change; Regulation FD disclosure; Other events24
  4. Aug 8, 20258-K Executive or director change; Shareholder vote25
  5. Aug 6, 20258-K Regulation FD disclosure; Other events26
  6. Jul 17, 20258-K Regulation FD disclosure; Other events27
  7. Jun 27, 20258-K Executive or director change; Bylaws or fiscal year changed; Regulation FD disclosure28
  8. Jun 24, 20258-K Regulation FD disclosure; Other events29
  9. Jun 9, 20258-K Entered a material agreement; Unregistered sale of shares; Executive or director change30
  10. Dec 20, 20248-K Executive or director change; Other events31
  11. Dec 6, 20248-K Shareholder vote32
  12. Oct 4, 20248-K Change of auditor33
  13. Jun 14, 2021New chief executive Alan J. Tuchman becomes CEO14

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202634

When it reported results

  1. Mar 7, 2023Reported quarterly or annual results35

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

173 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 33 major events, 64 insider forms, 6 large holders, 3 private raises, 46 other. The latest 20:

  1. Oct 9, 2026S-3/A EDGAR
  2. Aug 13, 202610-Q EDGAR
  3. Jun 5, 202610-K/A EDGAR
  4. May 19, 20264 OWNERSHIP DOCUMENT EDGAR
  5. May 19, 20264 OWNERSHIP DOCUMENT EDGAR
  6. May 19, 20264 OWNERSHIP DOCUMENT EDGAR
  7. May 19, 20264 OWNERSHIP DOCUMENT EDGAR
  8. May 19, 20264 OWNERSHIP DOCUMENT EDGAR
  9. May 13, 202610-Q EDGAR
  10. Apr 8, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Apr 8, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Apr 8, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Mar 31, 202610-K EDGAR
  14. Feb 5, 20265 OWNERSHIP DOCUMENT EDGAR
  15. Jan 2, 2026S-8 EDGAR
  16. Jan 2, 2026S-3/A EDGAR
  17. Dec 19, 20258-K EDGAR
  18. Nov 21, 2025EFFECT EDGAR
  19. Nov 19, 2025CORRESP EDGAR
  20. Nov 17, 2025DEF 14A EDGAR

The 173 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 0 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 16, 2022Singer William S.DirectorSale27,000$1.17$31.6KForm 4
Dec 16, 2022WEINSTEIN ROBERTChief Financial OfficerSale27,000$1.17$31.6KForm 4
Dec 16, 2022Silverman JoshuaExecutive ChairmanSale19,012$1.17$22.2KForm 4
Dec 16, 2022SCHECHTER JONATHANDirectorSale20,250$1.17$23.7KForm 4
Dec 16, 2022Alkon Daniel L.President and CSOSale19,688$1.17$23.0KForm 4
Dec 16, 2022Bernstein BruceDirectorSale22,500$1.17$26.3KForm 4
Dec 16, 2022TUCHMAN ALAN JChief Medical OfficerSale27,000$1.17$31.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$19.7M 2024–2025
Money received by yearMoney received by year, 2024–2025: $19.7M in all. Private raises (Form D) $19.7M.$0$5M$10M$15M$20M2024 · Private raises (Form D): $3.2M20242025 · Private raises (Form D): $16.5M2025
Figures by year
YearPrivate raises (Form D)Total
2025$16.5M$16.5M
2024$3.2M$3.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Oct 13, 2025Raised $11 million in a private offering of equity21 Form D: 7 investors so far Form D
  2. Jun 9, 2025Raised $5.5 million in a private offering of equity39 Form D: 5 investors so far Form D
  3. Sep 10, 2024Raised $3.2 million in a private offering of equity40 Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC118,471$441.9K0.0%+39,102
Citadel Advisors LLC83,172$310.2K0.0%New
Geode Capital Management, LLC79,374$296.3K0.0%−9,270
Renaissance Technologies LLC78,817$294.0K0.0%−22,983
Summit Financial, LLC57,760$215.4K0.0%+14,485
Jane Street Group, LLC54,854$204.6K0.0%New
BlackRock, Inc.45,898$171.2K0.0%+26,145
UBS Group AG32,779$122.3K0.0%+22,029
Vanguard Fiduciary Trust Co31,889$118.9K0.0%−13,543
State Street Corp25,200$94.0K0.0%+5,900
Morgan Stanley24,359$90.9K0.0%No change
Northern Trust Corp13,923$51.9K0.0%+1,797
Dimensional Fund Advisors LP12,619$47.1K0.0%No change
Blue Trust, Inc.2,832$10.6K0.0%No change
Steward Partners Investment Advisory, LLC2,800$10.4K0.0%No change
MassMutual Private Wealth & Trust, FSB2,700$10.1K0.0%No change
Tower Research Capital LLC (TRC)2,413$9.0K0.0%+2,337
PNC Financial Services Group, Inc.750$2.8K0.0%No change
SBI Securities Co., Ltd.520$1.9K0.0%New
Colonial Trust Advisors500$1.9K0.0%New
Osaic Holdings, Inc.220$8200.0%No change
Barclays PLC117$4360.0%New
Jones Financial Companies Lllp70$2510.0%No change
Federation des caisses Desjardins du Quebec50$1870.0%−400
Hrt Financial LP40,072$1490.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How TAO Synergies Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTAO Synergies Inc.1
  • CIK0001571934
  • Employer ID (EIN)46-15856565
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)6199 Finance Services1
  • SEC reviewing officeOffice of Crypto Assets, Division of Corporation Finance1
  • Business address1185 Avenue Of The Americas, 3Rd Floor, New York, NY 100361
  • Phone97324200051
  • Shares outstanding7,483,242 as of Aug 13, 202613
  • Public float$19.4M as of Jun 30, 20255
  • AuditorStephano Slack LLC, Wayne, Pennsylvania PCAOB ID 3523; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceMar 13, 20131
  • Filings241 in all: 4 (60), 8-K (43), 10-Q (18), 4/A (12), CORRESP (10), 3 (9), DEF 14A (8), EFFECT (8)1
    All 30 form types

    D (7), PRE 14A (7), SC 13G/A (7), 10-K (6), S-3 (6), UPLOAD (6), 424B3 (4), S-1/A (4), S-8 (4), ARS (3), DEFA14A (3), S-1 (3), SC 13G (3), S-3/A (2), 10-K/A (1), 3/A (1), 424B1 (1), 424B5 (1), 5 (1), 8-A12B (1), CERT (1), DRS (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Nov 17, 2025
    Latest 8-K (8-K) Dec 19, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par valueper shareTAOXNasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks TAO Synergies Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 72 risks under these headings, as written.5

  • Risks Related to Our Digital Asset Strategy and Holdings
  • Our adoption of a digital asset treasury strategy centered on TAO and participation in the Bittensor network may not be successfully implemented and exposes us to significant operational, market, cybersecurity, and regulatory risks.
  • We may seek to raise additional capital in the future to support our digital asset treasury strategy, including the acquisition of TAO, and we cannot predict the timing of any such financing.
  • Our financial results are heavily dependent on TAO, significantly increasing our exposure to crypto asset market volatility, valuation uncertainty, and concentrated credit risks.
  • If we fail to successfully implement our crypto asset-related business strategy, or if our strategy proves ineffective, our business, financial condition and results of operations could be materially and adversely affected.
  • Bittensor’s TAO token, generated via a decentralized “Proof-of-Intelligence” mining process, faces significant volatility, governance centralization risks, regulatory uncertainty, limited liquidity, and ongoing security vulnerabilities related to its AI-focused consensus model and underlying decentralized infrastructure.
  • The open-source and decentralized design of crypto asset networks, including the Bittensor network on which the TAO crypto asset functions, exposes us to risks related to forks, air drops, incidental rights, and related technological and operational disruptions.
  • Our operating results are dependent on the price of TAO. If such price declines, our business, operating results, and financial condition would be adversely affected.
  • Certain of our directors, officers, employees and independent contractors may hold crypto assets.
  • We are highly dependent on James Altucher and other key personnel, and our inability to retain or attract experienced individuals could materially harm our business.
  • Our TAO holdings are likely to be less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents.
  • Regulatory change classifying certain digital cryptocurrency assets as “securities” could lead to our being subject to extensive regulation, which could result in significant costs or force us to cease operations.
The other 61 risks
  • We will likely need to pursue additional equity or debt financings to meet our previously announced goal of acquiring $100 million of TAO.
  • Our historical financial statements do not reflect the potential variability in earnings that we may experience in the future relating to our proposed holdings of crypto assets.
  • The emergence or growth of other crypto assets, including those with significant private or public sector backing, could have a negative impact on the price of TAO and adversely affect our business.
  • Risks Related to the Custodian and Prime Broker
  • We face additional risks related to our reliance on BitGo Prime LLC (the “Prime Broker”) and BitGo Trust Company, Inc. (the “Custodian”), which are affiliated entities, for trading, custody, and settlement of TAO.
  • Security threats to the Company’s account at the Custodian could result in the halting of the Company’s operations and a loss of the Company’s assets or damage to the reputation of the Company, each of which could materially and adversely affect the Company.
  • Risks Related to Staking
  • Staking activities involve significant risks, including the risks of borrower default, operational failures and the potential loss of TAO, which could materially and adversely affect our financial performance and the value of our crypto assets.
  • Our reliance on the Custodian and its third-party validator for TAO staking activities creates concentration and related risks.
  • Our TAO staking relies on the Custodian and our Validators, who may utilize subnet automated market maker (“AMM”) pools, exposing us to additional liquidity, market, and operational risks beyond our direct control.
  • If crypto assets held by us are determined to be securities under U.S. federal or state law, we would become subject to significant regulatory burdens, which may materially and adversely affect its business, operations, and financial condition.
  • Risks Related to Our Media Platform
  • Our ownership and operation of The TAO Daily, an online news publication and data provider in the digital asset industry, presents a number of significant risks, including those arising from perceived or actual conflicts of interest.
  • Our strategy and focus on delivering high-quality, regulated, easy-to-use, and secure digital asset-related information through our media platform The TAO Daily may not maximize short-term or medium-term financial results.
  • Our success depends on our ability to effectively improve and scale our technical and data infrastructure.
  • Security incidents and other network and information systems disruptions could affect our ability to conduct our business effectively, cause us to incur significant costs, subject us to significant liability and/or damage our reputation.
  • We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.
  • Our failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business.
  • Our business depends on continued and unimpeded access to the internet and cloud-based hosting services we utilize.
  • Our advertising revenues are affected by numerous factors, including market dynamics, evolving digital advertising trends and the evolution of our strategy.
  • The open-source structure of crypto asset networks, including the Bittensor network on which the TAO crypto asset functions, exposes us to risks related to software development, security vulnerabilities, and potential disruptions.
  • The irreversibility of crypto asset transactions exposes us to risks of theft, loss and human error, which could negatively impact our business.
  • Decentralized AI networks, such as Bittensor, involve special risks related to unclear regulatory requirements, technical difficulties, limited transparency, intense competition, and complex intellectual property considerations.
  • Crypto Asset Regulatory Risks
  • We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds, or to obligations applicable to investment advisers or other regulated entities.
  • Engaging in certain activities involving crypto assets classified as commodities, such as offering futures, derivatives, leveraged transactions, or providing trading advice or brokerage services, could subject us to additional regulation by the Commodity Futures Trading Commission (“CFTC”), and potentially oversight by the National Futures Association (“NFA”).
  • Potential classification of our crypto asset activities including staking as money transmission could subject us to additional regulatory requirements, resulting in significant compliance costs or the cessation of certain operations.
  • Regulatory scrutiny or shifting enforcement priorities could subject our crypto asset activities to significant compliance costs, legal liabilities, and operational disruptions, even absent formal classification as securities or commodities.
  • Additional Crypto Asset Risks
  • Changes in tax law or adverse positions by tax authorities regarding crypto assets could result in increased tax burdens, reporting requirements, or other negative consequences.
  • Environmental and social risks associated with crypto assets could lead to negative market perceptions of TAO and materially harm its value.
  • Risks Related to Our Business and Financial Condition
  • Our exploration and pursuit of strategic alternatives may not be successful.
  • Our ongoing viability as a company partially depends on our ability to successfully develop and commercialize our licensed technology.
  • If the CRE License were terminated, we may be required to cease product development operations.
  • We rely on independent third-party contract research organizations to perform clinical and non-clinical studies of our drug candidate and to perform other research and development services.
  • We have relied on the representations and materials provided by CRE, including scientific, peer-reviewed and non-peer reviewed publications, abstracts, slides, internal documents, verbal communications, patents and related patent filings, with respect to the results of its research related to our proposed products.
  • We have a limited operating history upon which investors can evaluate our future prospects.
  • If we do not obtain the necessary regulatory approvals in the United States and/or other countries, we will not be able to sell our drug candidate(s).
  • The commencement and completion of clinical trials can be delayed or prevented for a number of reasons.
  • Even if regulatory approvals are obtained for our product candidates, we will be subject to ongoing government regulation. If we fail to comply with applicable current and future laws and government regulations, it could delay or prevent the promotion, marketing or sale of our products.
  • Data from our Bryostatin-1 Phase 2 clinical trial, from our confirmatory Phase 2 clinical trial and our expanded Phase 2 clinical trial may be subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share the Company’s views of the data.
  • Our commercial success will depend, in part, on our ability, and the ability of our licensors, to obtain and maintain patent protection. Our licensors’ failure to obtain and maintain patent protection for our products may have a material adverse effect on our product development business.
  • Our licensed patented technologies may infringe on other patents, which may expose us to costly litigation.
  • We may not be able to protect our trade secrets and other unpatented proprietary technologies, which could give our competitors an advantage over us.
  • If we are unable to hire additional qualified personnel, our business prospects may suffer.
  • We may not be able to in-license or acquire new development-stage products or technologies.
  • We are partly dependent upon the NCI to supply bryostatin for our clinical trials.
  • We expect to rely on third parties to manufacture our proposed products and, as a result, we may not be able to control our product development or commercialization.
  • We may rely on third parties for marketing and sales and our revenue prospects may depend on their efforts.
  • If our products are not accepted by patients, the medical community or health insurance companies, our business prospects will suffer.
  • The branded prescription segment of the pharmaceutical industry in which we operate is competitive, and we are particularly subject to the risks of such competition.
  • Our business will expose us to potential product liability risks, which could result in significant product liability exposure.
  • A successful clinical trial liability claim against us could have a material adverse effect on our financial condition even with such insurance coverage.
  • A successful liability claim against us could have a material adverse effect on our financial condition.
  • Reforms in the healthcare industry and the uncertainty associated with pharmaceutical and laboratory test pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products.
  • Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent our drug candidates from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business rely, which could negatively impact our business.
  • Our business and operations would suffer in the event of computer system failures.
  • Consolidation in the pharmaceutical industry could materially affect our ability to operate as an independent entity.
  • We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the military conflict between Russia and Ukraine and armed conflicts between Israel and Hamas. Our business, financial condition and results of operations may be materially and adversely affected by any negative impact on the global economy and capital markets resulting from the conflicts in Ukraine, the Gaza Strip or any other geopolitical tensions.
  • Any of the above-mentioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military actions, sanctions and resulting market disruptions are impossible to predict, but could be substantial.
  • Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could materially and adversely affect us.
  • Our employees, independent contractors, principal investigators, contract research organizations, consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Risks Relating to our Common Stock and the Securities Market
  • The market price of our common stock has been volatile.
  • In addition, in the past, following periods of volatility in the overall market and the market price of a particular company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.
  • If we fail to meet the continued listing standards of Nasdaq, our common stock may be delisted, which may adversely affect the market price and liquidity of our common stock.
  • A significant number of our shares of Common Stock are or will be eligible for future sale, which may cause the market price for our Common Stock to decline.

Legal proceedings

There are no legal proceedings against the Company and the Company is unaware of any such proceedings contemplated against it.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceTAOX quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40